"Boronic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
| Descriptor ID |
D001897
|
| MeSH Number(s) |
D01.029.260.110 D01.132.285 D02.203.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Boronic Acids".
Below are MeSH descriptors whose meaning is more specific than "Boronic Acids".
This graph shows the total number of publications written about "Boronic Acids" by people in this website by year, and whether "Boronic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 4 | 1 | 5 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 2 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 4 | 5 | 9 |
| 2012 | 4 | 2 | 6 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Boronic Acids" by people in Profiles.
-
A biomimetic fluorescent nanosensor based on imprinted polymers modified with carbon dots for sensitive detection of alpha-fetoprotein in clinical samples. Analyst. 2019 Nov 04; 144(22):6760-6772.
-
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257.
-
Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient. J Antimicrob Chemother. 2018 12 01; 73(12):3529-3531.
-
Reversal of hyperactive Wnt signaling-dependent adipocyte defects by peptide boronic acids. Proc Natl Acad Sci U S A. 2017 09 05; 114(36):E7469-E7478.
-
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015 Jul; 170(1):66-79.
-
Synthesis of many different types of organic small molecules using one automated process. Science. 2015 Mar 13; 347(6227):1221-6.
-
Bortezomib prevents acute doxorubicin ovarian insult and follicle demise, improving the fertility window and pup birth weight in mice. PLoS One. 2014; 9(9):e108174.
-
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
-
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.
-
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013 Oct; 163(1):55-61.